L-Ornithine L-Aspartate Injection
- Packing: 10 Ml Ampoule.
- Available Strength : 5 Gm, 10 Ml
Description
Product Description: L-Ornithine L-Aspartate Injection is a sterile solution containing the amino acids L-ornithine and L-aspartate. It is formulated for intravenous administration and is used to manage conditions associated with impaired liver function, such as hepatic encephalopathy. These amino acids play a role in the urea cycle and help facilitate the detoxification of ammonia in the liver.
Indications and Usage: L-Ornithine L-Aspartate Injection is indicated for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with liver dysfunction. It is used to reduce elevated ammonia levels in the blood and improve symptoms such as confusion, altered consciousness, and neuromuscular disturbances.
Dosage and Administration: The dosage of L-Ornithine L-Aspartate Injection depends on the severity of hepatic encephalopathy and the patient's response to therapy. It is typically administered intravenously at a recommended dose of 5-10 grams per day, divided into multiple doses. The duration of treatment may vary depending on the individual patient's condition.
Dosage Forms and Strengths: L-Ornithine L-Aspartate Injection is available as a sterile solution for intravenous administration. It is commonly supplied in vials containing various strengths, typically ranging from 5 grams to 10 grams per vial.
Contraindications: L-Ornithine L-Aspartate Injection is contraindicated in patients with hypersensitivity to any component of the formulation. It should also be avoided in patients with severe liver failure or severe renal impairment.
Warnings and Precautions: Use caution when administering L-Ornithine L-Aspartate Injection to patients with impaired renal function or electrolyte imbalances. Monitor serum electrolytes, renal function, and ammonia levels regularly during therapy. Avoid rapid infusion to minimize the risk of adverse reactions.
Adverse Reactions/Side Effects: Common adverse reactions associated with L-Ornithine L-Aspartate Injection may include gastrointestinal upset, nausea, vomiting, and diarrhea. Rarely, allergic reactions or electrolyte imbalances may occur. Monitoring for signs of adverse reactions is recommended during therapy.
Drug Interactions: There are no known significant drug interactions with L-Ornithine L-Aspartate Injection. However, it is essential to review the patient's medication profile for potential interactions with other drugs they may be receiving concurrently.
Use In Specific Populations Description: Safety and efficacy of L-Ornithine L-Aspartate Injection in pediatric patients, pregnant women, and nursing mothers have not been established. Use caution and consult with a healthcare professional before administering to individuals in these populations.
How Supplied/Storage and Handling: L-Ornithine L-Aspartate Injection is supplied as a sterile solution in vials for intravenous administration. It should be stored at controlled room temperature (20°C to 25°C) away from light and moisture. Care should be taken to ensure proper storage and handling to maintain the integrity of the product. Unused portions should be discarded according to standard procedures for biohazardous waste.